@article{3ed3230842b946bd9a0043e32b7f346e,
title = "A concise and persistent feature to study brain resting-state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative",
abstract = "Alzheimer's disease (AD) is the most common type of dementia in the elderly with no effective treatment currently. Recent studies of noninvasive neuroimaging, resting-state functional magnetic resonance imaging (rs-fMRI) with graph theoretical analysis have shown that patients with AD and mild cognitive impairment (MCI) exhibit disrupted topological organization in large-scale brain networks. In previous work, it is a common practice to threshold such networks. However, it is not only difficult to make a principled choice of threshold values, but also worse is the discard of potential important information. To address this issue, we propose a threshold-free feature by integrating a prior persistent homology-based topological feature (the zeroth Betti number) and a newly defined connected component aggregation cost feature to model brain networks over all possible scales. We show that the induced topological feature (Integrated Persistent Feature) follows a monotonically decreasing convergence function and further propose to use its slope as a concise and persistent brain network topological measure. We apply this measure to study rs-fMRI data from the Alzheimer's Disease Neuroimaging Initiative and compare our approach with five other widely used graph measures across five parcellation schemes ranging from 90 to 1,024 region-of-interests. The experimental results demonstrate that the proposed network measure shows more statistical power and stronger robustness in group difference studies in that the absolute values of the proposed measure of AD are lower than MCI and much lower than normal controls, providing empirical evidence for decreased functional integration in AD dementia and MCI.",
keywords = "Alzheimer's disease, functional connectivity, network measure, persistent homology, resting-state functional magnetic resonance imaging, rips filtration",
author = "{for the Alzheimer's Disease Neuroimaging Initiative} and Liqun Kuang and Xie Han and Kewei Chen and Caselli, {Richard J.} and Reiman, {Eric M.} and Yalin Wang",
note = "Funding Information: Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroIm-mun; F. Hoffmann-La Roche Ltd and its affiliated company Genen-tech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: information: National Natural Science Foundation of China, Grant/Award Numbers: 61379080, 61672473, 61602426; National Institute on Aging, Grant/Award Numbers: R21AG043760, RF1AG051710, R01AG031581, P30AG19610; National Institute of Biomedical Imaging and Bioengineering, Grant/Award Number: R01EB025032; National Institutes of Health, Grant/Award Numbers: U54EB020403, U01AG024904; National Science Foundation, Division of Information and Intelligent Systems, Grant/Award Number: IIS-1421165; National Science Foundation, Division of Mathematical Sciences, Grant/Award Number: DMS-1413417; DOD ADNI, Grant/Award Number: W81XWH-12-2-0012This work was partially supported by the National Natural Science Foundation of China (61379080, 61672473, and 61602426 for LK and XH); National Institute on Aging (R21AG043760 and RF1AG051710 to YW, R01AG031581 and P30AG19610 to RJC and EMR), National Institute of Biomedical Imaging (R01EB025032 to YW), National Institutes of Health BD2K award (U54EB020403 to YW), and National Science Foundation (DMS-1413417 and IIS-1421165 to YW). Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. Funding Information: This work was partially supported by the National Natural Science Foundation of China (61379080, 61672473, and 61602426 for LK and XH); National Institute on Aging (R21AG043760 and RF1AG051710 to YW, R01AG031581 and P30AG19610 to RJC and EMR), National Institute of Biomedical Imaging (R01EB025032 to YW), National Institutes of Health BD2K award (U54EB020403 to YW), and National Science Foundation (DMS-1413417 and IIS-1421165 to YW). Funding Information: National Natural Science Foundation of China, Grant/Award Numbers: 61379080, 61672473, 61602426; National Institute on Aging, Grant/ Award Numbers: R21AG043760, RF1AG051710, R01AG031581, P30AG19610; National Institute of Biomedical Imaging and Bioengineering, Grant/Award Number: R01EB025032; National Institutes of Health, Grant/Award Numbers: U54EB020403, U01AG024904; National Science Foundation, Division of Information and Intelligent Systems, Grant/Award Number: IIS-1421165; National Science Foundation, Division of Mathematical Sciences, Grant/Award Number: DMS-1413417; DOD ADNI, Grant/Award Number: W81XWH-12-2-0012 Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2019",
month = mar,
doi = "10.1002/hbm.24383",
language = "English (US)",
volume = "40",
pages = "1062--1081",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "4",
}